Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.45 +0.69%
Revenue Growth %: +40.6%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
CRMT, More
Revenue Growth %: +40.6%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of $0.53, $0.19 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $123.9 million versus the consensus estimate of $123.01 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
